Morganite Crucible (India) Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 8, 2025, 7:44 pm

Quick Insight

Morganite Crucible (India) Ltd's current share price of ₹1,513, with a P/E ratio of 30.5, indicates the market's confidence in the company's future earnings potential. The robust ROE of 21.4% and ROCE of 30.4% reflect efficient capital allocation and strong operational performance. However, the low ICR of 0.00x raises concerns about the company's ability to meet its debt obligations. With a healthy OPM of 15.48% and a solid reserve base of ₹129 Cr, Morganite Crucible has a strong financial foundation. Investors should closely monitor the company's debt levels and cash conversion cycle (CCC) to ensure sustainable growth and profitability in the long term.

Competitors of Morganite Crucible (India) Ltd

All Competitor Stocks of Morganite Crucible (India) Ltd

Quarterly Result

Last Updated: July 15, 2025, 5:25 pm

Below is a detailed analysis of the quarterly data for Morganite Crucible (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 42.32 Cr.. The value appears to be declining and may need further review. It has decreased from 44.66 Cr. (Dec 2024) to 42.32 Cr., marking a decrease of 2.34 Cr..
• For Expenses, as of Mar 2025, the value is 35.77 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 34.18 Cr. (Dec 2024) to 35.77 Cr., marking an increase of 1.59 Cr..
• For Operating Profit, as of Mar 2025, the value is 6.55 Cr.. The value appears to be declining and may need further review. It has decreased from 10.48 Cr. (Dec 2024) to 6.55 Cr., marking a decrease of 3.93 Cr..
• For OPM %, as of Mar 2025, the value is 15.48%. The value appears to be declining and may need further review. It has decreased from 23.47% (Dec 2024) to 15.48%, marking a decrease of 7.99%.
• For Other Income, as of Mar 2025, the value is 1.52 Cr.. The value appears to be declining and may need further review. It has decreased from 2.75 Cr. (Dec 2024) to 1.52 Cr., marking a decrease of 1.23 Cr..
• For Interest, as of Mar 2025, the value is 0.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.05 Cr. (Dec 2024) to 0.03 Cr., marking a decrease of 0.02 Cr..
• For Depreciation, as of Mar 2025, the value is 2.62 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.31 Cr. (Dec 2024) to 2.62 Cr., marking an increase of 0.31 Cr..
• For Profit before tax, as of Mar 2025, the value is 5.42 Cr.. The value appears to be declining and may need further review. It has decreased from 10.87 Cr. (Dec 2024) to 5.42 Cr., marking a decrease of 5.45 Cr..
• For Tax %, as of Mar 2025, the value is 46.86%. The value appears to be increasing, which may not be favorable. It has increased from 27.78% (Dec 2024) to 46.86%, marking an increase of 19.08%.
• For Net Profit, as of Mar 2025, the value is 2.88 Cr.. The value appears to be declining and may need further review. It has decreased from 7.85 Cr. (Dec 2024) to 2.88 Cr., marking a decrease of 4.97 Cr..
• For EPS in Rs, as of Mar 2025, the value is 5.14. The value appears to be declining and may need further review. It has decreased from 14.02 (Dec 2024) to 5.14, marking a decrease of 8.88.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 12:41 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:01 pm

Below is a detailed analysis of the balance sheet data for Morganite Crucible (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
• For Reserves, as of Mar 2025, the value is 129.00 Cr.. The value appears strong and on an upward trend. It has increased from 126.00 Cr. (Mar 2024) to 129.00 Cr., marking an increase of 3.00 Cr..
• For Borrowings, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 38.00 Cr.. The value appears to be improving (decreasing). It has decreased from 45.00 Cr. (Mar 2024) to 38.00 Cr., marking a decrease of 7.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 170.00 Cr.. The value appears to be improving (decreasing). It has decreased from 174.00 Cr. (Mar 2024) to 170.00 Cr., marking a decrease of 4.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 81.00 Cr.. The value appears strong and on an upward trend. It has increased from 62.00 Cr. (Mar 2024) to 81.00 Cr., marking an increase of 19.00 Cr..
• For CWIP, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 4.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 86.00 Cr.. The value appears to be declining and may need further review. It has decreased from 112.00 Cr. (Mar 2024) to 86.00 Cr., marking a decrease of 26.00 Cr..
• For Total Assets, as of Mar 2025, the value is 170.00 Cr.. The value appears to be declining and may need further review. It has decreased from 174.00 Cr. (Mar 2024) to 170.00 Cr., marking a decrease of 4.00 Cr..

Notably, the Reserves (129.00 Cr.) exceed the Borrowings (1.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Morganite Crucible (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 17, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 16) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 17, the value is 51.87. This value is within the healthy range. It has increased from 35.67 (Mar 16) to 51.87, marking an increase of 16.20.
• For Diluted EPS (Rs.), as of Mar 17, the value is 51.87. This value is within the healthy range. It has increased from 35.67 (Mar 16) to 51.87, marking an increase of 16.20.
• For Cash EPS (Rs.), as of Mar 17, the value is 75.38. This value is within the healthy range. It has increased from 66.81 (Mar 16) to 75.38, marking an increase of 8.57.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 343.51. It has increased from 285.76 (Mar 16) to 343.51, marking an increase of 57.75.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 343.51. It has increased from 285.76 (Mar 16) to 343.51, marking an increase of 57.75.
• For Revenue From Operations / Share (Rs.), as of Mar 17, the value is 397.75. It has increased from 392.35 (Mar 16) to 397.75, marking an increase of 5.40.
• For PBDIT / Share (Rs.), as of Mar 17, the value is 109.55. This value is within the healthy range. It has increased from 95.26 (Mar 16) to 109.55, marking an increase of 14.29.
• For PBIT / Share (Rs.), as of Mar 17, the value is 91.91. This value is within the healthy range. It has increased from 65.59 (Mar 16) to 91.91, marking an increase of 26.32.
• For PBT / Share (Rs.), as of Mar 17, the value is 91.91. This value is within the healthy range. It has increased from 65.59 (Mar 16) to 91.91, marking an increase of 26.32.
• For Net Profit / Share (Rs.), as of Mar 17, the value is 57.74. This value is within the healthy range. It has increased from 37.14 (Mar 16) to 57.74, marking an increase of 20.60.
• For NP After MI And SOA / Share (Rs.), as of Mar 17, the value is 51.87. This value is within the healthy range. It has increased from 35.67 (Mar 16) to 51.87, marking an increase of 16.20.
• For PBDIT Margin (%), as of Mar 17, the value is 27.54. This value is within the healthy range. It has increased from 24.28 (Mar 16) to 27.54, marking an increase of 3.26.
• For PBIT Margin (%), as of Mar 17, the value is 23.10. This value exceeds the healthy maximum of 20. It has increased from 16.71 (Mar 16) to 23.10, marking an increase of 6.39.
• For PBT Margin (%), as of Mar 17, the value is 23.10. This value is within the healthy range. It has increased from 16.71 (Mar 16) to 23.10, marking an increase of 6.39.
• For Net Profit Margin (%), as of Mar 17, the value is 14.51. This value exceeds the healthy maximum of 10. It has increased from 9.46 (Mar 16) to 14.51, marking an increase of 5.05.
• For NP After MI And SOA Margin (%), as of Mar 17, the value is 13.04. This value is within the healthy range. It has increased from 9.09 (Mar 16) to 13.04, marking an increase of 3.95.
• For Return on Networth / Equity (%), as of Mar 17, the value is 16.56. This value is within the healthy range. It has increased from 13.64 (Mar 16) to 16.56, marking an increase of 2.92.
• For Return on Capital Employeed (%), as of Mar 17, the value is 26.60. This value is within the healthy range. It has increased from 22.62 (Mar 16) to 26.60, marking an increase of 3.98.
• For Return On Assets (%), as of Mar 17, the value is 12.30. This value is within the healthy range. It has increased from 9.59 (Mar 16) to 12.30, marking an increase of 2.71.
• For Asset Turnover Ratio (%), as of Mar 17, the value is 1.00. It has increased from 0.98 (Mar 16) to 1.00, marking an increase of 0.02.
• For Current Ratio (X), as of Mar 17, the value is 4.01. This value exceeds the healthy maximum of 3. It has increased from 3.14 (Mar 16) to 4.01, marking an increase of 0.87.
• For Quick Ratio (X), as of Mar 17, the value is 3.27. This value exceeds the healthy maximum of 2. It has increased from 2.41 (Mar 16) to 3.27, marking an increase of 0.86.
• For Inventory Turnover Ratio (X), as of Mar 17, the value is 2.26. This value is below the healthy minimum of 4. It has increased from 2.14 (Mar 16) to 2.26, marking an increase of 0.12.
• For Dividend Payout Ratio (NP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 11.21 (Mar 16) to 0.00, marking a decrease of 11.21.
• For Dividend Payout Ratio (CP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 6.12 (Mar 16) to 0.00, marking a decrease of 6.12.
• For Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 88.79 (Mar 16) to 0.00, marking a decrease of 88.79.
• For Cash Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 93.88 (Mar 16) to 0.00, marking a decrease of 93.88.
• For Interest Coverage Ratio (X), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 16) which recorded 0.00.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 16) which recorded 0.00.
• For Enterprise Value (Cr.), as of Mar 17, the value is 210.89. It has increased from 92.31 (Mar 16) to 210.89, marking an increase of 118.58.
• For EV / Net Operating Revenue (X), as of Mar 17, the value is 1.89. This value is within the healthy range. It has increased from 0.84 (Mar 16) to 1.89, marking an increase of 1.05.
• For EV / EBITDA (X), as of Mar 17, the value is 6.87. This value is within the healthy range. It has increased from 3.46 (Mar 16) to 6.87, marking an increase of 3.41.
• For MarketCap / Net Operating Revenue (X), as of Mar 17, the value is 2.23. This value is within the healthy range. It has increased from 1.04 (Mar 16) to 2.23, marking an increase of 1.19.
• For Retention Ratios (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 88.78 (Mar 16) to 0.00, marking a decrease of 88.78.
• For Price / BV (X), as of Mar 17, the value is 2.83. This value is within the healthy range. It has increased from 1.56 (Mar 16) to 2.83, marking an increase of 1.27.
• For Price / Net Operating Revenue (X), as of Mar 17, the value is 2.23. This value is within the healthy range. It has increased from 1.04 (Mar 16) to 2.23, marking an increase of 1.19.
• For EarningsYield, as of Mar 17, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.08 (Mar 16) to 0.05, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness